Tsai Tsung-Ying, Chen Kuan-Jen, Chao An-Ning
Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou, Taiwan.
Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Taiwan J Ophthalmol. 2022 Dec 21;13(4):556-559. doi: 10.4103/2211-5056.364566. eCollection 2023 Oct-Dec.
We report a case of successful management of intravitreal injections of anti-vascular endothelial growth factor antibody bevacizumab in two unusual complications, preretinal neovascularization and vitreous hemorrhage, secondary to a combined hamartoma of the retina and retinal pigment epithelium (CHRRPE). A male pediatric patient suffered from decreased vision in the right eye at 5-year-old. His ophthalmologic examination revealed a CHRRPE involving the superior area of the optic disc and macula in the right eye. The patient's family history and neurological examinations of tuberous sclerosis were absent. While no lesion growth was observed over time, preretinal vascularization and recurrent nonclearing hemorrhage occurred 2 years after the initial presentation. The patient was successfully managed with two intravitreal injections of bevacizumab. No recurrences of vitreous hemorrhage were observed at a 7-year post-treatment follow-up. Intravitreal injections of bevacizumab were safe and effective in the management of uncommon complications of preretinal neovascularization and vitreous hemorrhage of CHRRPE in a pediatric patient in long-term follow-up.
我们报告了一例成功治疗玻璃体内注射抗血管内皮生长因子抗体贝伐单抗的病例，该病例出现了两种不寻常的并发症，即视网膜前新生血管形成和玻璃体积血，这是由视网膜和视网膜色素上皮联合错构瘤（CHRRPE）继发引起的。一名男性儿科患者5岁时右眼视力下降。他的眼科检查发现右眼视盘上方区域和黄斑区有CHRRPE。患者家族史中无结节性硬化症，神经系统检查也未发现异常。虽然随着时间推移未观察到病变生长，但在初次就诊2年后出现了视网膜前血管形成和反复不吸收的出血。该患者通过两次玻璃体内注射贝伐单抗成功治愈。治疗后7年的随访中未观察到玻璃体积血复发。在长期随访中，玻璃体内注射贝伐单抗对于治疗儿科患者CHRRPE引起的视网膜前新生血管形成和玻璃体积血等罕见并发症是安全有效的。
